Hydronephrosis Treatment Market Size to Surpass US$4.31 Billion by 2033, The Brainy Insights [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
The market will experience rapid growth due to technological advancements in imaging techniques during the forecast period. Newark, April 29, 2024 (GLOBE NEWSWIRE) -- The Brainy Insights estimates that the USD 2 billion in 2023 global hydronephrosis treatment market will reach USD 4.31 billion in 2033. A medical disorder called hydronephrosis is characterized by the expansion or swelling of one or both kidneys due to pee buildup. This happens when there is an obstruction in the flow of urine, which kidney stones, tumours, UTIs, congenital anomalies, or scar tissue can cause. The degree and underlying aetiology of hydronephrosis determine the course of treatment. Managing pain is frequently the first action. Solving the underlying issue is essential. For example, shock wave lithotripsy can be used to break down kidney stones, or surgery can be used to remove them. A ureteral stent may be placed in some situations to help with urine flow, or surgery may be required to clear obstructio
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- U.S. FDA approves Amgen drug for small cell lung cancer [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCERPR Newswire
- FDA Approves Amgen Drug for Persistently Deadly Form of Lung Cancer [The New York Times]The New York Times
- FDA approves Amgen's treatment for most deadly form of lung cancer [CNBC]CNBC
- Amgen Drug Wins US Approval for Advanced Small Cell Lung Cancer [BNN Bloomberg (Canada)]BNN Bloomberg
AMGN
Earnings
- 5/2/24 - Beat
AMGN
Sec Filings
- 5/10/24 - Form DEFA14A
- 5/9/24 - Form 4
- 5/9/24 - Form 4
- AMGN's page on the SEC website